Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Table 1

Patient demographics and baseline characteristics.

Variables	Normal-weight patients (N = 17)	Overweight and obese patients (N = 10)	value
Age, y	60.47 ± 10.88	56.1 ± 15.21	0.392
HbA1c, %	8.54 ± 1.03	8.89 ± 1.07	0.413
FPG, mmol/L	9.92 ± 2.92	11.17 ± 2.99	0.301
eGFR, ml/min/1.73 m^2	100.9 ± 12.32	105.8 ± 14.18	0.372
BMI, kg/m^2	21.82 ± 1.27	26.75 ± 1.97	<0.0001
FIB, g/L	2.89 ± 0.68	2.88 ± 0.64	0.963
hs-CRP, mg/L	1.83 ± 1.89	4.79 ± 3.78	0.012
Irisin, pg/mL	71.04 ± 5.9	73.75 ± 4.66	0.252
8-oxo-gsn, ng/mL	6.58 ± 0.55	6.65 ± 0.42	0.701
NT-proBNP, pg/mL	220.2 ± 25.5	202.9 ± 19.18	0.111

Data are reported as the mean ± SD. value was analyzed by the mean change comparison between normal-weight patients and overweight and obese patients. HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; eGFR: estimated glomerular filtration rate; BMI: body mass index; NT-proBNP: N-terminal probrain natriuretic peptide.